Drugs / BBT-877
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04138849 | Oct 2019 | — | Bridge Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04138836 | Sep → Nov 2019 | — | Bridge Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03830125 | Feb → Nov 2019 | idiopathic pulmonary fibrosis | Bridge Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05483907 | Apr 2023 → Jan 2025 | idiopathic pulmonary fibrosis | Bridge Biotherapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBT-877 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03830125 ↗ |
| Action | Inhibit | “BBT-877: an autotaxin inhibitor targeting idiopathic pulmonary fibrosis.” PMID 40404183 ↗ May 2025 |
| Route | Oral | “oral capsule” NCT03830125 ↗ |